{"id":57996,"date":"2023-09-04T16:04:07","date_gmt":"2023-09-04T14:04:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/gene-fusion-testing-market-poised-for-12-25-cagr-targeted-therapy-development-drives-growth-researchandmarkets-com\/"},"modified":"2023-09-04T16:04:07","modified_gmt":"2023-09-04T14:04:07","slug":"gene-fusion-testing-market-poised-for-12-25-cagr-targeted-therapy-development-drives-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/gene-fusion-testing-market-poised-for-12-25-cagr-targeted-therapy-development-drives-growth-researchandmarkets-com\/","title":{"rendered":"Gene Fusion Testing Market Poised for 12.25% CAGR: Targeted Therapy Development Drives Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Gene Fusion Testing Market – A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region – Analysis and Forecast, 2023-2033”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe global gene fusion testing market witnessed a value of $255.3 million in 2022 and is projected to reach $897.6 million by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 12.25% during the forecast period from 2023 to 2033. This growth is driven by the increasing utilization of gene fusion testing in the development of targeted therapies.<\/p>\n

\nMarket Lifecycle Stage:<\/strong><\/p>\n

\nThe global gene fusion testing market is currently in the progressing phase. The market is experiencing rapid growth due to the rise in cancer incidence attributed to gene fusion mutations. The need for early detection, precise targeted therapy selection, personalized medicine, and the growing recognition and implementation of gene fusion testing in clinical settings are driving the demand for these diagnostic tests in cancer care.<\/p>\n

\nImpact:<\/strong><\/p>\n

\nGene fusion testing involves molecular analysis to detect genetic abnormalities, specifically gene fusions. These arise when two genes from different chromosomal locations join abnormally, resulting in a hybrid gene formation. Such fusions can lead to the creation of abnormal proteins or changes in gene expression, potentially contributing to the development of diseases, including specific types of cancer. In addition to this, the entry of established players like Amoy Diagnostics Co., Ltd., Roche, Guardant Health, Illumina, and others is expected to further boost market growth.<\/p>\n

\nArtificial Intelligence (AI)-powered prediction models have the potential to identify patients who need further diagnostic tests, reducing the need for time-consuming and expensive laboratory assays. These models can uncover novel, previously undetected gene fusion events, enhancing the understanding of the genomic landscape of malignancies and assisting in designing targeted therapies.<\/p>\n

\nMarket Segmentation:<\/strong><\/p>\n

    \n
  1. \n

    \nCategory:<\/strong><\/p>\n